Status: Recommended with restrictions | |||
Cariprazine (Reagila®) is recommended as an option for restricted use within NHS Wales. Cariprazine (Reagila®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of schizophrenia in adults:
Cariprazine (Reagila®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
Medicine name | cariprazine (Reagila®) | ||
Formulation | 1.5 mg, 3 mg, 4.5 mg, 6 mg hard capsules | ||
Reference number | 5032 | ||
Indication | Treatment of schizophrenia in adult patients |
||
Company | Recordati Pharmaceuticals Ltd | ||
BNF chapter | Central nervous system | ||
Submission type | Resubmission | ||
Status | Recommended with restrictions | ||
Advice number | 0822 | ||
NMG meeting date | 02/03/2022 | ||
AWMSG meeting date | 27/04/2022 | ||
Date of issue | 12/05/2022 |